课题基金 / 基金详情

Immunomodulatory properties of umbilical cord blood

Immunomodulatory properties of umbilical cord blood
脐带血的免疫调节特性
批准号:
8461805
负责人:
MAKIO IWASHIMA
金额:
$17.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-02-01 至 2015-01-31

项目摘要

项目成果

MAKIO IWASHIMA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Fetal and neonatal immune system is known to be immature and antigen stimulation can cause tolerance rather than effector responses. Monocytes in peripheral blood differentiate to macrophages and dendritic cells (DC) which drive adaptive immunity, and they also likely provide cytokine support for T-independent B cell responses. We have recently identified two populations of monocytes (CD14+) in cord blood, CD36hi and CD36low and shown that the CD36hi monocytes drive development of regulatory T (Treg) cells. Study suing specific inhibitors showed that induction of Tregs require TGF-? signaling while IL-10, retinoic acid, or aryl hydrocarbon receptor signaling is not required. CD36h monocytes express the latent form of TGF-? complex on the cell surface. We hypothesize that the immunosuppressive state of infants is due in part to the predominance of these immunosuppressive CD36hi monocytes which promote expansion of Treg cells. We also hypothesize that membrane-bound TGF-? provides a signaling process required for generation of Tregs. In Aim 1, we will examine the mechanism by which TGF-? is attached to the cell membrane of CD36hi monocytes. In Aim 2, we will monitor localization of TGF-? receptor complex and its down stream target molecules during induction of Foxp3+ Tregs by CD36hi monocytes. Results from these studies are expected to provide a basis for understanding fetal/neonatal tolerance and will help developing safer and long lasting immunesuppression. The outcomes of this study will also help overcoming the immunocompromised state of infants by a combination of more effective vaccine adjuvants that will abrogate the immunosuppressive state of infants as well as enhance their immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Function of Siglec 5 in T cell activation.
  • 批准号:
    10373619
  • 项目类别:
  • 资助金额:
    $18.45万
  • 财政年份:
    2022
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
Function of Siglec 5 in T cell activation.
  • 批准号:
    10665549
  • 项目类别:
  • 资助金额:
    $22.3万
  • 财政年份:
    2022
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
Immune checkpoint modulation by bacterial metabolites.
  • 批准号:
    10246854
  • 项目类别:
  • 资助金额:
    $22.25万
  • 财政年份:
    2020
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
Immunomodulatory properties of umbilical cord blood
  • 批准号:
    8606811
  • 项目类别:
  • 资助金额:
    $21.76万
  • 财政年份:
    2013
  • 负责人:
    MAKIO IWASHIMA
  • 依托单位:
海外基金